Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CVRx, Inc. stock logo
CVRX
CVRx
$8.00
-4.2%
$6.45
$4.30
$18.55
$208.56M1.23308,917 shs358,405 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.39
+1.5%
$1.89
$1.30
$12.33
$50.97M1.31844,497 shs1.87 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$31.26
-2.9%
$27.91
$23.15
$125.68
$12.09B1.848.97 million shs7.81 million shs
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
$3.50
-1.1%
$3.80
$2.03
$8.45
$180.95M2.47207,279 shs80,708 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CVRx, Inc. stock logo
CVRX
CVRx
0.00%+17.13%+36.52%+32.01%-14.53%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
0.00%+2.21%-29.08%-21.91%-86.20%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-7.07%+20.69%+24.39%-74.20%
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
0.00%+2.64%-13.79%+26.81%-54.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CVRx, Inc. stock logo
CVRX
CVRx
3.0621 of 5 stars
3.41.00.00.03.34.20.6
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
3.7565 of 5 stars
3.33.00.04.40.60.01.3
Moderna, Inc. stock logo
MRNA
Moderna
4.2476 of 5 stars
4.01.00.04.61.82.50.6
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
1.5562 of 5 stars
2.12.00.00.01.83.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CVRx, Inc. stock logo
CVRX
CVRx
2.86
Moderate Buy$14.5081.25% Upside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.60
Moderate Buy$8.80533.09% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.6149.11% Upside
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
2.29
Hold$3.9312.38% Upside

Current Analyst Ratings Breakdown

Latest INO, MRNA, CVRX, and SGHT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2025
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$3.00 ➝ $4.00
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold ➝ Hold
7/9/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$5.00
7/7/2025
CVRx, Inc. stock logo
CVRX
CVRx
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/18/2025
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.50 ➝ $4.00
6/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
5/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$33.00 ➝ $26.00
5/22/2025
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.20 ➝ $3.60
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$5.00 ➝ $5.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CVRx, Inc. stock logo
CVRX
CVRx
$51.29M4.07N/AN/A$2.93 per share2.73
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$220K231.69N/AN/A$1.90 per share0.73
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.74N/AN/A$28.33 per share1.10
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
$79.87M2.27N/AN/A$1.72 per share2.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CVRx, Inc. stock logo
CVRX
CVRx
-$59.97M-$2.18N/AN/AN/A-97.49%-79.04%-42.37%8/4/2025 (Estimated)
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$107.25M-$3.19N/AN/AN/AN/A-136.93%-89.99%8/6/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-105.67%-28.69%-21.94%8/1/2025 (Estimated)
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
-$51.51M-$0.98N/AN/AN/A-63.24%-54.62%-34.92%7/30/2025 (Estimated)

Latest INO, MRNA, CVRX, and SGHT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.65N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
-$0.25N/AN/AN/A$18.18 millionN/A
8/4/2025Q2 2025
CVRx, Inc. stock logo
CVRX
CVRx
-$0.52N/AN/AN/AN/AN/A
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.97N/AN/AN/A$116.26 millionN/A
5/13/2025Q1 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.74-$0.51+$0.23-$0.51$0.01 million$0.07 million
5/8/2025Q1 2025
CVRx, Inc. stock logo
CVRX
CVRx
-$0.56-$0.53+$0.03-$0.53$14.68 million$12.35 million
5/8/2025Q1 2025
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
-$0.29-$0.28+$0.01-$0.28$16.51 million$17.51 million
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CVRx, Inc. stock logo
CVRX
CVRx
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CVRx, Inc. stock logo
CVRX
CVRx
0.71
14.82
13.45
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
2.63
2.63
Moderna, Inc. stock logo
MRNA
Moderna
N/A
4.22
4.14
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
0.51
10.47
9.99

Institutional Ownership

CompanyInstitutional Ownership
CVRx, Inc. stock logo
CVRX
CVRx
75.27%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
55.51%

Insider Ownership

CompanyInsider Ownership
CVRx, Inc. stock logo
CVRX
CVRx
18.90%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.30%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
28.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
CVRx, Inc. stock logo
CVRX
CVRx
16026.07 million21.15 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32036.67 million35.83 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800386.74 million344.20 millionOptionable
Sight Sciences, Inc. stock logo
SGHT
Sight Sciences
21051.70 million36.76 millionOptionable

Recent News About These Companies

Sight Sciences (NASDAQ:SGHT) Rating Lowered to Sell at Wall Street Zen
SGHT - Sight Sciences Inc Chart - Morningstar
Sight Sciences Leads The Pack Of 3 Promising Penny Stocks

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CVRx stock logo

CVRx NASDAQ:CVRX

$8.00 -0.35 (-4.19%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$8.00 0.00 (0.00%)
As of 07/18/2025 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.39 +0.02 (+1.46%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.41 +0.02 (+1.44%)
As of 07/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Moderna stock logo

Moderna NASDAQ:MRNA

$31.26 -0.94 (-2.92%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$31.26 -0.01 (-0.02%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Sight Sciences stock logo

Sight Sciences NASDAQ:SGHT

$3.50 -0.04 (-1.13%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$3.50 +0.00 (+0.14%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.